CD8<sup>+</sup> T cell killing of ovcan cells improved following pre-treatment with PAK inhibitors, and this was further augmented with PD-1 blockade.<h4>Discussion</h4>The work presented here demonstrates the efficacy of PAK inhibition and PD-1 checkpoint blockade as a combination therapy for high-grade serous ovarian cancer. The gene discussed is CD8A; the disease is ovarian serous adenocarcinoma.